Montironi R - Search Results

1

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer.

Devlies W, Eckstein M, Cimadamore A, Devos G, Moris L, Van den Broeck T, Montironi R, Joniau S, Claessens F, Gevaert T. Devlies W, et al. Among authors: montironi r. Cells. 2020 Nov 17;9(11):2494. doi: 10.3390/cells9112494. Cells. 2020. PMID: 33212909 Free PMC article. Review.

2

Active surveillance for low-risk prostate cancer.

Mazzucchelli R, Nesseris I, Cheng L, Lopez-Beltran A, Montironi R, Scarpelli M. Mazzucchelli R, et al. Among authors: montironi r. Anticancer Res. 2010 Sep;30(9):3683-92. Anticancer Res. 2010. PMID: 20944154 Review.

3

Role of histopathology and molecular markers in the active surveillance of prostate cancer.

Montironi R, Egevad L, Bjartell A, Berney DM. Montironi R, et al. Acta Oncol. 2011 Jun;50 Suppl 1:56-60. doi: 10.3109/0284186X.2010.522199. Acta Oncol. 2011. PMID: 21604942 Review.

4

Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.

Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB. Karantanos T, et al. Among authors: montironi r. Eur Urol. 2015 Mar;67(3):470-9. doi: 10.1016/j.eururo.2014.09.049. Epub 2014 Oct 8. Eur Urol. 2015. PMID: 25306226 Free PMC article. Review.

5

Small cell carcinoma of the prostate: molecular basis and clinical implications.

Wang L, Davidson DD, Montironi R, Lopez-Beltran A, Zhang S, Williamson SR, MacLennan GT, Wang C, Wang M, Emerson RE, Du X, Cheng L. Wang L, et al. Among authors: montironi r. Histol Histopathol. 2015 Apr;30(4):413-24. doi: 10.14670/HH-30.413. Epub 2014 Nov 10. Histol Histopathol. 2015. PMID: 25383744 Review.

6

Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression and overexpression of EGFR.

Simper NB, Jones CL, MacLennan GT, Montironi R, Williamson SR, Osunkoya AO, Wang M, Zhang S, Grignon DJ, Eble JN, Tran T, Wang L, Baldrige LA, Cheng L. Simper NB, et al. Among authors: montironi r. Hum Pathol. 2015 Jun;46(6):805-12. doi: 10.1016/j.humpath.2015.02.004. Epub 2015 Feb 26. Hum Pathol. 2015. PMID: 25870120

7

Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies.

Santoni M, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Cheng L, Epstein JI, Cascinu S, Briganti A, Catto JW, Montorsi F, Montironi R. Santoni M, et al. Among authors: montironi r. Eur Urol. 2016 Feb;69(2):186-90. doi: 10.1016/j.eururo.2015.05.041. Epub 2015 Jun 10. Eur Urol. 2016. PMID: 26070514 Free article.

8

Metabolic Alterations in Renal and Prostate Cancer.

Ciccarese C, Santoni M, Massari F, Modena A, Piva F, Conti A, Mazzucchelli R, Cheng L, Lopez-Beltran A, Scarpelli M, Tortora G, Montironi R. Ciccarese C, et al. Among authors: montironi r. Curr Drug Metab. 2016;17(2):150-5. doi: 10.2174/1389200216666151015112356. Curr Drug Metab. 2016. PMID: 26467063 Review.

9

Grading of prostate cancer in the 21st century.

Epstein JI, Montironi R. Epstein JI, et al. Among authors: montironi r. Urologia. 2016 Jan-Mar;83(1):1-3. doi: 10.5301/uro.5000163. Epub 2015 Dec 14. Urologia. 2016. PMID: 26689535 No abstract available.

10

AR-V7 and prostate cancer: The watershed for treatment selection?

Ciccarese C, Santoni M, Brunelli M, Buti S, Modena A, Nabissi M, Artibani W, Martignoni G, Montironi R, Tortora G, Massari F. Ciccarese C, et al. Among authors: montironi r. Cancer Treat Rev. 2016 Feb;43:27-35. doi: 10.1016/j.ctrv.2015.12.003. Epub 2015 Dec 18. Cancer Treat Rev. 2016. PMID: 26827690 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,016 results

Search Page